Direkt zum Inhalt
Merck
  • Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis.

Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis.

American heart journal (2015-11-07)
Richard Brandon Stacey, Paul E Leaverton, Douglas D Schocken, Jennifer A Peregoy, Alain G Bertoni
ZUSAMMENFASSUNG

With one-quarter of initial myocardial infarctions (MI) being unrecognized MI (UMI), recognition is critical to minimize further cardiovascular risk. Diabetes mellitus is an established risk factor for UMI. If impaired fasting glucose (IFG) also increased the risk for UMI, it would represent a significant public health challenge due to the rapid worldwide increase in IFG prevalence. We compared participants with IFG to those with normal fasting glucose (NFG) to determine if IFG was associated with UMIs. We performed cross-sectional analyses from the MESA, a population-based cohort study. There were 6,814 participants recruited during July 2000 to September 2002 from the general community at 6 field sites. After excluding those with diabetes mellitus or missing variables, 5,885 participants were included. At baseline, there were 4,955 participants with NFG and 930 participants with IFG. The main outcome was an UMI defined by the presence of pathological Q waves or minor Q waves with ST-T abnormalities on initial 12-lead electrocardiogram. Logistic regression was used to generate crude ORs and adjust for covariates. There was a higher prevalence of UMI in those with IFG compared with those with NFG [3.5% (n = 72) vs 1.4% (n = 30)]. After adjustment for multiple risk factors, there was a higher odds of an UMI among those with IFG compared with those with NFG [OR: 1.60 (95% CI: 1.0-2.5); P = .048]. Impaired fasting glucose is associated with unrecognized myocardial infarctions in a multi-ethnic population free of baseline cardiovascular disease.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Glycerin, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycerin, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glycerin, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Cholesterin, Sigma Grade, ≥99%
Sigma-Aldrich
Glycerin, ≥99.5%
Sigma-Aldrich
Glycerin -Lösung, 83.5-89.5% (T)
Sigma-Aldrich
Cholesterin, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Glycerin, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerin, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glycerin, BioXtra, ≥99% (GC)
Sigma-Aldrich
SyntheChol® NS0-Supplement, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Sigma-Aldrich
Glycerin, FCC, FG
Sigma-Aldrich
Cholesterin, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
Glycerin, meets USP testing specifications
Supelco
Cholesterin -Lösung, certified reference material, 10 mg/mL in chloroform
SAFC
Cholesterin, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
Cholesterin, from lanolin, ≥99.0% (GC)